This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

This study has been completed.
Information provided by:
Novartis Identifier:
First received: December 15, 2006
Last updated: May 28, 2010
Last verified: May 2010
The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.

Condition Intervention Phase
Tumors Drug: Patupilone Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Dose-limiting Toxicity [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • Safety and tolerability of patupilone assessed by CTCAE [ Time Frame: 18 months ]
  • Pharmacokinetic profile of patupilone [ Time Frame: 18 months ]
  • Anti-tumor activity of patupilone according to the RECIST guidelines [ Time Frame: 18 months ]

Enrollment: 15
Study Start Date: August 2006
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EPO906 Drug: Patupilone
Other Name: EPO906


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with a histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to or unsuitable for standard therapy, or for whom no standard therapy exists
  • Patients with WHO Performance Status of 0-1 ( Karnofsky Performance Status of 80-100)
  • At least one measurable lesion

Exclusion criteria:

  • Patients with any peripheral neuropathy
  • Patients with unresolved diarrhea
  • Patients with severe and/or uncontrolled medical conditions or infections that require systemic therapy

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00412789

Novartis Investigative Site
Tokyo, Japan
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00412789     History of Changes
Other Study ID Numbers: CEPO906A1103
Study First Received: December 15, 2006
Last Updated: May 28, 2010

Keywords provided by Novartis:
Advanced solid tumor

Additional relevant MeSH terms:
Epothilone B
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on June 21, 2017